The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
|Articles|September 2, 2014
- Pharmaceutical Technology-09-02-2014
- Volume 38
- Issue 9
Xylem Polarimeters Measure Chiral Compounds
The ADP600 Series high accuracy Peltier temperature-controlled polarimeters from Xylem?s Bellingham + Stanley brand measure chiral compounds and other optically active substances.
Advertisement
The ADP600 Series high accuracy Peltier temperature-controlled polarimeters from Xylem’s Bellingham + Stanley brand measure chiral compounds and other optically active substances. The polarimeters are available as single, dual, and multiple wavelength derivatives covering the visible spectrum and the ultraviolet region. ADP600 polarimeters have an extensive interfacing capability and may be configured to operate in secure environments in accordance with FDA regulation 21 CFR Part 11 and also meet the requirements of US, European, and Japanese pharmacopeia. A full-color, high-definition touchscreen graphical user interface simplifies operation. A full range of accessories is available including low-volume, standard, and flow-through sample tubes as well as United Kingdom Accreditation Service-certified, quartz control plates.
Articles in this issue
about 12 years ago
Using Ultrasonic Cleaning for Equipment and Toolingabout 12 years ago
Investigation of Various Impurities in Febuxostatabout 12 years ago
Asymmetric Synthesis Continues to Advanceabout 12 years ago
Using Quality by Design to Develop Robust Chromatographic Methodsabout 12 years ago
Waters QTof Mass Spectrometer Detects Low-Level Compoundsabout 12 years ago
Extending the Scope of Pharmacovigilance Comes at a Priceabout 12 years ago
Minimizing Variation in Vial Withdrawal Practiceabout 12 years ago
The Relevance of Industry Technical Associationsabout 12 years ago
Thermo Fisher Scientific UHPLC System Improves Productivityabout 12 years ago
Excellims Ion-Mobility Separator Interfaces with Mass SpectrometersAdvertisement
Related to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Advertisement
Advertisement